Emily L Bossard

TL;DR: Head-to-head evaluation of different SARS-CoV-2 neutralization platforms could facilitate comparisons across studies and laboratories, and high concordance between the outcomes of cell-based assays with live and pseudotyped virions enables valid cross-study comparison using these platforms.

TL;DR: A cross-sectional seroprevalence study of IgG antibodies for nucleocapsid of SARS-CoV-2 among the residents of Blaine County, Idaho, a ski resort community with high COVID-19 attack rates suggests the community is not yet near the herd immunity threshold.

TL;DR: Using plasma samples from COVID-19 convalescent individuals with mild-to-moderate disease from a localized outbreak in a single region of the western US, three platforms for SARS-CoV-2 neutralization are compared: assay with live SARS/pseudovirus, pseudovirus assay utilizing lentiviral and vesicular stomatitis virus packaging, and a surrogate ELISA test.

TL;DR: In this article, single-cell RNA-Seq approaches to simultaneously define gene expression and TCR clonotypes of the human ectocervix were used to identify distinct populations of CD8+ T cells with IFNGhiGZMBloCD69hiCD103lo or IFNGloGZMBhiCD69medCD103hi phenotypes.

TL;DR: In this paper, a human monoclonal antibody (OC2) was used to neutralize the live virus derived from the original isolate of the human Betacoronavirus OC43.